Menu Close

Artikel-artikel mengenai Pharmaceuticals

Menampilkan 21 - 40 dari 201 artikel

While pills come in many shapes and sizes, they all eventually reach your bloodstream and travel throughout your body. Vadim Sazhniev/iStock via Getty Images

How do drugs know where to go in the body? A pharmaceutical scientist explains why some medications are swallowed while others are injected

From tablets and patches to ointments and infusions, the best way to deliver a drug is the one that gets the right amount to the right place.
From thalidomide to Viagra, drug repurposing salvaged failed treatments by giving them new targets. smartboy10/DigitalVision Vectors via Getty Images

Repurposing generic drugs can reduce time and cost to develop new treatments – but low profitability remains a barrier

Drug repurposing can redeem failed treatments and squeeze out new uses from others. But many pharmaceutical companies are hesitant to retool existing drugs without a high return on investment.
Generic drug names are assigned at the global level by the World Health Organization in conjunction with national naming authorities. (Shutterstock)

Generic drug names provide information for doctors, so why is Health Canada promoting the use of pharma brand names?

Generic drug names are often long, but they can tell doctors what type of medicine it is and how it works. But it’s brand names that appear first and most prominently in Health Canada materials.
Until the late 19th century, patenting medicines was considered by some as controversial and even unethical. S. Vannini/De Agostini Editorial via Getty Images

The US drug industry used to oppose patents – what changed?

The pharmaceutical industry overall has been deeply opposed to waiving COVID-19 vaccine patents, but a historian of the industry explains that drug companies once opposed patents altogether.
Though drug recalls are relatively uncommon in the U.S., reduced inspections increase the likelihood of manufacturing errors that slip through the cracks. AP Photo/Rafiq Maqbool

The FDA’s weak drug manufacturing oversight is a potentially deadly problem

COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.

Kontributor teratas

Lebih banyak